Marc Peeters Selected Research

Panitumumab (Vectibix)

10/2020	Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy.
6/2020	Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G.
12/2019	Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
1/2019	Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study.
11/2018	Impact of Emergent Circulating Tumor DNA RAS Mutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer.
2/2018	Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials.
1/2018	Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
1/2018	Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials.
1/2018	Author Correction: Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials.
1/2018	Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marc Peeters Research Topics

Disease

109	Neoplasms (Cancer) 07/2022 - 03/2006
75	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 09/2005
16	Neoplasm Metastasis (Metastasis) 01/2022 - 09/2005
13	Squamous Cell Carcinoma of Head and Neck 01/2022 - 05/2010
13	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2021 - 06/2011
12	Hypoxia (Hypoxemia) 01/2020 - 03/2006
11	Adenocarcinoma 01/2022 - 08/2005
11	Disease Progression 02/2021 - 08/2005
9	Pancreatic Neoplasms (Pancreatic Cancer) 02/2021 - 10/2008
6	Breast Neoplasms (Breast Cancer) 10/2020 - 01/2014
6	Head and Neck Neoplasms (Head and Neck Cancer) 03/2020 - 10/2010
5	Carcinoma (Carcinomatosis) 01/2022 - 08/2005
5	Fatigue 10/2019 - 12/2011
5	Colonic Neoplasms (Colon Cancer) 01/2018 - 02/2011
4	Lung Neoplasms (Lung Cancer) 01/2021 - 05/2010
4	Primitive Neuroectodermal Tumors (PNET) 05/2018 - 04/2015
3	Carcinogenesis 01/2022 - 09/2017
3	Glioblastoma (Glioblastoma Multiforme) 10/2021 - 01/2018
3	Circulating Neoplastic Cells 04/2021 - 12/2014
3	Rectal Neoplasms (Rectal Cancer) 04/2021 - 02/2007
3	Deglutition Disorders (Dysphagia) 03/2020 - 09/2015
3	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2019 - 01/2018
3	Vomiting 01/2017 - 04/2009
3	Exanthema (Rash) 12/2011 - 04/2009
2	Inflammation (Inflammations) 07/2022 - 01/2016
2	Cholangiocarcinoma 07/2022 - 02/2017
2	Body Weight (Weight, Body) 07/2022 - 11/2011
2	Pain (Aches) 07/2022 - 11/2017
2	Microsatellite Instability 12/2021 - 09/2019
2	Ovarian Neoplasms (Ovarian Cancer) 10/2021 - 02/2008
2	Lymphatic Metastasis 01/2021 - 05/2019
2	Triple Negative Breast Neoplasms 01/2020 - 01/2014
2	Anemia 10/2019 - 10/2009
2	Diarrhea 01/2019 - 01/2016
2	Hypertension (High Blood Pressure) 01/2019 - 09/2009
2	Autosomal Dominant 5 Deafness 01/2018 - 05/2017

Drug/Important Bio-Agent (IBA)

29	ErbB Receptors (EGF Receptor)IBA 01/2022 - 04/2008
25	Biomarkers (Surrogate Marker)IBA 01/2022 - 11/2010
25	Panitumumab (Vectibix)FDA Link 10/2020 - 05/2007
22	Cetuximab (Erbitux)FDA Link 01/2022 - 09/2008
16	Proteins (Proteins, Gene)FDA Link 01/2022 - 10/2009
15	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2021 - 09/2005
10	Monoclonal AntibodiesIBA 10/2020 - 11/2010
10	Gemcitabine FDA Link 01/2017 - 08/2005
9	Fluorouracil (Carac)FDA LinkGeneric 01/2019 - 04/2009
9	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2019 - 02/2008
9	Irinotecan (Camptosar)FDA LinkGeneric 01/2019 - 04/2009
8	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 04/2008
8	Messenger RNA (mRNA)IBA 05/2019 - 10/2009
8	Leucovorin (Folinic Acid)FDA Link 01/2019 - 04/2009
6	Cell-Free Nucleic AcidsIBA 01/2022 - 01/2018
6	regorafenibIBA 12/2021 - 11/2014
6	Pharmaceutical PreparationsIBA 02/2021 - 12/2011
5	Phosphotransferases (Kinase)IBA 01/2022 - 11/2010
5	Bevacizumab (Avastin)FDA Link 06/2020 - 11/2011
5	Circulating Tumor DNAIBA 03/2019 - 12/2014
5	Cisplatin (Platino)FDA LinkGeneric 04/2018 - 09/2015
4	Immune Checkpoint InhibitorsIBA 07/2022 - 01/2018
4	LigandsIBA 01/2022 - 10/2009
4	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 11/2021 - 11/2012
4	MicroRNAs (MicroRNA)IBA 11/2021 - 01/2016
4	RNA (Ribonucleic Acid)IBA 01/2020 - 01/2014
4	Biological ProductsIBA 01/2019 - 08/2013
3	Tyrosine Kinase InhibitorsIBA 07/2022 - 07/2009
3	Tumor Biomarkers (Tumor Markers)IBA 01/2022 - 03/2015
3	PlatinumIBA 01/2021 - 01/2016
3	AntibodiesIBA 10/2020 - 10/2018
3	BI 6727IBA 11/2019 - 10/2015
3	Polo-Like Kinase 1IBA 11/2019 - 01/2017
3	Oxygen (Dioxygen)IBA 10/2019 - 06/2015
3	AfatinibIBA 01/2019 - 10/2015
3	SirtuinsIBA 12/2018 - 01/2016
3	Formaldehyde (Formol)FDA Link 10/2018 - 10/2009
3	ParaffinIBA 10/2018 - 10/2009
3	trifluridine tipiracil drug combinationIBA 07/2018 - 05/2015
3	Yttrium-90IBA 01/2017 - 08/2010
3	Everolimus FDA Link 03/2016 - 12/2011
3	Sunitinib (Sutent)FDA Link 11/2014 - 07/2009
3	Glucose (Dextrose)FDA LinkGeneric 01/2009 - 02/2008
2	NivolumabIBA 07/2022 - 04/2021
2	thiamine triphosphorate (TTP)IBA 01/2022 - 08/2010
2	ChemokinesIBA 11/2021 - 01/2018
2	CytokinesIBA 11/2021 - 09/2020
2	Auranofin (Ridaura)FDA Link 10/2021 - 01/2021
2	Poly I-CIBA 06/2021 - 01/2018
2	Interleukin-15 (Interleukin 15)IBA 01/2020 - 08/2017
2	Denosumab FDA Link 05/2019 - 01/2017
2	Therapeutic UsesIBA 01/2019 - 01/2011
2	eprenetapoptIBA 04/2018 - 06/2016
2	Hypoxia-Inducible Factor 1IBA 04/2018 - 08/2014

Therapy/Procedure

60	Therapeutics 07/2022 - 04/2009
32	Drug Therapy (Chemotherapy) 02/2021 - 09/2005
16	Radiotherapy 04/2021 - 03/2006
8	Immunotherapy 06/2021 - 04/2012
5	Chemoradiotherapy 01/2021 - 10/2010
3	Continuity of Patient Care 07/2018 - 08/2013
3	Microspheres (Microsphere) 01/2017 - 08/2010
2	Drug Tapering 01/2020 - 01/2018
2	Duration of Therapy 01/2018 - 11/2017
2	Adjuvant Chemotherapy 01/2018 - 01/2018